Nautilus reveals the setup and testing of its external field evaluation unit.

Written by Emily J. Thompson, Senior Investment Analyst

NAUT+0.52%

Updated: Nov 03 2025

0mins

Nautilus Biotechnology's Achievement: Nautilus Biotechnology successfully installed and tested its first external field evaluation unit, generating reproducible data from neurodegenerative disease samples over six months.
Collaboration with Buck Institute: The collaboration with the Buck Institute aims to utilize the Nautilus Proteome Analysis Platform to investigate tau proteoforms related to Alzheimer's and neurodegeneration.
Future Reporting: Initial findings from this research will be presented at the 2025 Human Proteome Organization World Congress.
Joint Publication Plans: There are plans for future joint publication efforts based on the research outcomes from the collaboration.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy NAUT?" and start using high-conviction signals backed by rigorous historical data.

Sign up today to access powerful investing tools and make smarter, data-driven decisions.

NAUT

$1.95+Infinity%1D

Analyst Views on NAUT

Wall Street analysts forecast NAUT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAUT is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.940

Low

2.50

Averages

2.50

High

2.50

Current: 1.940

Low

2.50

Averages

2.50

High

2.50

No data

About NAUT

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NAUT?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NAUT?

Get Started Free